Sodium Hyaluronate 88mg/4mL Single Injection — Viscosupplement for Knee Osteoarthritis Pain Relief
Monovisc® (Sodium Hyaluronate) — Single-Injection Viscosupplementation for Knee Osteoarthritis
A Sourcing Guide for Hospitals and Orthopaedic Clinics
Monovisc® is a high molecular weight, cross-linked sodium hyaluronate viscosupplement indicated, according to its approved labelling, for the treatment of pain in patients with osteoarthritis (OA) of the knee who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. As with all intra-articular injection therapies, the decision to administer Monovisc rests entirely with the treating orthopaedic specialist or physician, in accordance with the approved label. This page provides sourcing and procurement information for hospitals and clinics, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Monovisc (Sodium Hyaluronate) 88mg/4mL pre-filled syringes to hospitals, orthopaedic clinics, and pharmacies across India, manufactured by Anika Therapeutics/Bioventus.
Monovisc contains a single, cross-linked formulation of high molecular weight sodium hyaluronate, derived from a bacterial fermentation process rather than animal sources.
Synovial Fluid and Osteoarthritis Pathophysiology:
According to published orthopaedic literature, healthy joints rely on synovial fluid, rich in hyaluronic acid, to provide lubrication and shock absorption between joint surfaces. In osteoarthritis, both the concentration and molecular weight of hyaluronic acid within synovial fluid decline, contributing to reduced joint lubrication, increased friction, and the pain and stiffness characteristic of the condition.
Monovisc’s Mechanism: By replenishing the joint space with cross-linked, high molecular weight sodium hyaluronate, Monovisc is intended to restore the viscoelastic, lubricating, and shock-absorbing properties of healthy synovial fluid, according to the manufacturer’s published information. Monovisc is formulated as a single-injection product, using cross-linking technology designed to extend the residence time of hyaluronic acid within the joint space compared to non-cross-linked formulations.
Full product information is available via the manufacturer’s Bioventus Monovisc resource, with additional background on osteoarthritis management available via the American Academy of Orthopaedic Surgeons and the Arthritis Foundation.
Single-Injection Clinical Data
According to data referenced by the manufacturer, Monovisc has been evaluated for pain relief and functional improvement in knee osteoarthritis patients following a single intra-articular injection, with published clinical information supporting its use as an alternative to multi-injection viscosupplementation courses.
Bacterial Fermentation-Derived Formulation
Monovisc’s hyaluronic acid is produced via bacterial fermentation rather than avian or animal-tissue extraction methods used in some other viscosupplement products, a manufacturing distinction the company notes as relevant for patients with concerns about animal-derived or avian-sourced medical products.
For broader clinical guidance on viscosupplementation and osteoarthritis management, the Osteoarthritis Research Society International (OARSI) publishes ongoing treatment guidelines.
Monovisc is supplied as:
| Presentation | Strength | Pack |
|---|---|---|
| Monovisc Pre-Filled Syringe | 88mg/4mL (22mg/mL) | Single-dose pre-filled syringe |
Monovisc is administered as a single intra-articular injection, distinguishing it from viscosupplement products requiring a multi-injection course.
Osteoarthritis of the Knee:
For detailed indication information refer to MedlinePlus Osteoarthritis and the CDC Osteoarthritis resource.
Single-Injection Treatment
Monovisc is formulated to deliver a complete treatment course in a single intra-articular injection, reducing the number of clinic visits required compared to multi-injection viscosupplementation products.
High Molecular Weight, Cross-Linked Formulation
The cross-linking process used in Monovisc’s manufacturing is designed to extend its residence time within the joint space, supporting sustained viscoelastic benefit from a single administration.
Bacterial Fermentation-Derived Hyaluronic Acid
Produced via bacterial fermentation rather than animal-tissue extraction, which the manufacturer notes as a relevant manufacturing distinction for some patients and clinicians.
Established Option in the Viscosupplementation Category
As part of a well-established treatment category, Monovisc provides physicians with an additional single-injection option alongside other hyaluronic acid-based viscosupplements.
Administration of Monovisc is performed by a qualified healthcare professional. General information from the manufacturer’s product materials includes:
Precautions During Administration:
Full administration guidelines are available in the manufacturer’s official product labelling and should always be followed exactly as directed by the treating physician.
Monovisc is administered by orthopaedic specialists, rheumatologists, and physicians experienced in intra-articular injection procedures for:
Monovisc is administered exclusively in a clinical setting. A.K. Pharma supplies Monovisc to hospitals and orthopaedic clinics across Delhi and India.
Common side effects reported include injection site reactions such as swelling, pain, and redness, along with general joint swelling and pain following administration, similar to other intra-articular hyaluronic acid products.
Precautions include:
Contraindication in Joint or Skin Infection: Monovisc should not be injected in patients with a knee joint infection or infection/skin disease at or near the injection site.
Hypersensitivity: Patients with known hypersensitivity to hyaluronate preparations should not receive Monovisc.
Post-Injection Activity Restrictions: Patients are typically advised to avoid strenuous activity, high-impact sports, and prolonged weight-bearing for a period following injection, per standard post-injection guidance for viscosupplementation products.
Full side effect information is available via the manufacturer’s official Monovisc product information.
As a responsible medicine distributor in Delhi, A.K. Pharma stores all orthopaedic products including Monovisc under manufacturer-recommended conditions ensuring product integrity for every supply.
Monovisc is manufactured by Anika Therapeutics and distributed by Bioventus. It is used by clinicians across numerous countries for single-injection knee osteoarthritis treatment. A.K. Pharma supplies only genuine Monovisc sourced from authorised distributors. Learn more about Bioventus’s orthopaedic portfolio directly from the manufacturer.
Q. What is Monovisc used for?
Monovisc (Sodium Hyaluronate) is used to treat pain associated with osteoarthritis of the knee in patients who have not responded adequately to conservative therapy or simple analgesics, administered as a single intra-articular injection.
Q. What is the active ingredient and strength of Monovisc?
Monovisc’s active ingredient is sodium hyaluronate, supplied at a strength of 88mg/4mL (22mg/mL) in a single-dose pre-filled syringe, manufactured by Anika Therapeutics and distributed by Bioventus.
Q. How is Monovisc different from Durolane?
Both are single-injection hyaluronic acid viscosupplements for knee osteoarthritis, but differ in strength, molecular formulation, and manufacturing source — Monovisc uses bacterial fermentation-derived hyaluronic acid at 88mg/4mL, while Durolane uses NASHA-processed hyaluronic acid at 60mg/3mL. Treatment selection is made by the treating physician based on clinical judgement.
Q. Is Monovisc derived from animal sources?
No. Monovisc’s hyaluronic acid is produced via bacterial fermentation, distinguishing it from some other viscosupplement products derived from avian or animal tissue sources.
Q. Is Monovisc available in India?
Monovisc can be supplied to hospitals and orthopaedic clinics across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi and pharmaceutical distributor in Delhi — for availability and pricing.
Q. What is the price of Monovisc in India?
Monovisc price in India varies by order quantity. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.
Q. How to order Monovisc from A.K. Pharma?
You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.
Q. Does A.K. Pharma supply Monovisc in bulk?
Yes. A.K. Pharma supplies Monovisc in bulk to hospitals and orthopaedic clinics across Delhi and India.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. All treatment decisions, including drug selection and administration, should be made by a qualified healthcare professional in accordance with the approved product labelling. A.K. Pharma is a licensed medicine distributor and does not provide clinical guidance.
